{"id":201095,"date":"2026-10-22T17:08:00","date_gmt":"2026-10-22T10:08:00","guid":{"rendered":"https:\/\/cell-lavie.com\/?p=201095"},"modified":"2026-10-14T14:28:13","modified_gmt":"2026-10-14T07:28:13","slug":"msc-therapy-for-alzheimers-disease-clinical-trial-data-on-laromestrocel-and-biomarker-outcomes","status":"publish","type":"post","link":"https:\/\/cell-lavie.com\/zh\/msc-therapy-for-alzheimers-disease-clinical-trial-data-on-laromestrocel-and-biomarker-outcomes\/","title":{"rendered":"MSC Therapy for Alzheimer&#8217;s Disease: Clinical Trial Data on Laromestrocel and Biomarker Outcomes"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Alzheimer&#8217;s disease affects millions worldwide, with no disease-modifying treatment available until now. Recent Phase 2a clinical trials have demonstrated that mesenchymal stem cell (MSC) therapy can slow brain atrophy and reduce neuroinflammation in mild Alzheimer&#8217;s patients. The laromestrocel trial, published in Nature Medicine in 2025, provides the first rigorous evidence that allogeneic bone marrow-derived MSCs can modify disease progression. This represents a shift from symptom management to targeting the underlying biology of neurodegeneration.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">At Cell La Vie, we follow this research closely as it represents a potential breakthrough for Thai patients and families facing Alzheimer&#8217;s diagnosis. This article reviews the latest clinical data, explains how MSC therapy works in neurodegenerative disease, and outlines what patients can expect from emerging treatment protocols.<\/p>\n\n\n\n<!--more-->\n\n\n\n<h2 class=\"wp-block-heading\">The Landmark Laromestrocel Phase 2a Trial<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">In April 2025, Longeveron Inc. published results from a randomized, double-blind, placebo-controlled Phase 2a trial testing laromestrocel-a bone marrow-derived, allogeneic MSC therapy-in 49 patients with mild Alzheimer&#8217;s disease across ten U.S. centers (Rash et al., Nature Medicine 2025). This is the largest and most rigorously designed MSC trial in Alzheimer&#8217;s to date, and its results have generated significant interest in the field.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Study Design and Dosing<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Participants were randomly assigned 1:1:1:1 to four groups:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Group 1 (Placebo): Four monthly intravenous infusions of saline (n=12)<\/li>\n\n\n\n<li>Group 2 (Low single): One infusion of 25 million cells followed by three monthly placebo infusions (n=13)<\/li>\n\n\n\n<li>Group 3 (Low repeated): Four monthly doses of 25 million cells each (n=13)<\/li>\n\n\n\n<li>Group 4 (High repeated): Four monthly doses of 100 million cells each (n=11)<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">This design allowed researchers to compare single vs. repeated dosing and low vs. high cell counts, providing dose-response data that most stem cell trials lack.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Safety Outcomes: No Serious Adverse Events<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The study met its primary endpoint of safety. Treatment-emergent serious adverse events within 4 weeks of infusion were similar across all groups:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table><thead><tr><th>Group<\/th><th>Serious Adverse Events<\/th><th>95% Confidence Interval<\/th><\/tr><\/thead><tbody><tr><td>Placebo<\/td><td>0%<\/td><td>0-26.5%<\/td><\/tr><tr><td>25M cells (single dose)<\/td><td>7.7%<\/td><td>0.2-36%<\/td><\/tr><tr><td>25M cells (four doses)<\/td><td>7.7%<\/td><td>0.2-36%<\/td><\/tr><tr><td>100M cells (four doses)<\/td><td>9.1%<\/td><td>0.2-41.3%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Most critically, no infusion-related reactions, hypersensitivities, or amyloid-related imaging abnormalities (ARIA) were reported. ARIA is a known side effect of anti-amyloid antibodies like lecanemab and aducanumab, which require regular MRI monitoring. The absence of ARIA with MSC therapy is a meaningful safety advantage, especially for elderly patients on blood thinners or with cardiovascular risk factors.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Efficacy: Slowed Brain Atrophy and Cognitive Decline<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">At 39 weeks, laromestrocel demonstrated disease-modifying effects across multiple endpoints:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Clinical assessments:<\/strong> Group 2 showed improvement on composite AD score (change: 0.38; 95% CI -0.06 to 0.82) vs placebo<\/li>\n\n\n\n<li><strong>Whole brain volume:<\/strong> 48.4% slower decline (p=0.005) across all treatment groups combined (n=32)<\/li>\n\n\n\n<li><strong>Left hippocampal volume:<\/strong> 61.9% slower decline (p=0.021, n=32)<\/li>\n\n\n\n<li><strong>Neuroinflammation:<\/strong> Reduced as measured by diffusion tensor imaging (DTI)<\/li>\n\n\n\n<li><strong>Clinical correlation:<\/strong> Bilateral hippocampal atrophy change correlated with MMSE scores (R=0.41, p=0.0075) in all 42 study patients<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The hippocampus is the brain region first affected in Alzheimer&#8217;s, responsible for memory formation and spatial navigation. Slowing atrophy here by nearly 62% directly translates to preserved cognitive function over time. The correlation between hippocampal volume and MMSE scores reinforces that brain structure preservation is clinically meaningful, not just a radiological curiosity.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Importantly, Montreal Cognitive Assessment (MoCA) and Activities of Daily Living (ADCS-ADL) scores also trended favorably, suggesting real-world functional benefits.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">How MSC Therapy Works in Alzheimer&#8217;s Disease<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Unlike traditional drugs that target a single pathological protein (amyloid-beta or tau), MSC therapy works through multiple complementary mechanisms. This multi-target approach is increasingly viewed as necessary for a disease as complex as Alzheimer&#8217;s.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">1. Immunomodulation and Neuroinflammation Reduction<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">MSCs secrete anti-inflammatory cytokines (IL-10, TGF-beta, PGE2) that modulate microglial activation. In Alzheimer&#8217;s, chronically activated microglia produce TNF-alpha and IL-1beta, which damage surrounding neurons. MSC therapy shifts microglia from a pro-inflammatory (M1) to a neuroprotective (M2) phenotype, reducing inflammatory cascading and preserving neurons.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">2. Blood-Brain Barrier Penetration via Exosomes<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">MSC-derived exosomes-nanosized extracellular vesicles (30-150 nm) carrying proteins, lipids, mRNA, and microRNA-can cross the blood-brain barrier (Patil et al., Brain and Behavior 2025). These exosomes deliver neurotrophic factors directly to brain tissue, promoting neuronal survival and synaptic plasticity. Exosome-based approaches are particularly promising because they offer the therapeutic benefits of whole cells without the risks of engraftment, uncontrolled differentiation, or tumor formation.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">3. Biomarker Modification<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">In a Korean Phase IIa trial (Lee et al., Dementia and Neurocognitive Disorders 2025), intraventricular MSC administration reduced cerebrospinal fluid levels of three key Alzheimer&#8217;s biomarkers:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Amyloid-beta 42 (Ab42)-the peptide that aggregates into plaques<\/li>\n\n\n\n<li>Phosphorylated tau (p-tau)-the protein that forms neurofibrillary tangles<\/li>\n\n\n\n<li>Total tau (t-tau)-a marker of neuronal damage and degeneration<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">These CSF biomarkers are the gold standard for measuring Alzheimer&#8217;s pathology in clinical research. Their reduction after MSC treatment indicates that the therapy targets the underlying disease process, not just clinical symptoms.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">4. Neuroprotection and Regeneration<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">MSCs secrete brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), and vascular endothelial growth factor (VEGF). These growth factors support neuronal survival, axonal growth, and angiogenesis in damaged brain regions. BDNF in particular has been shown to enhance synaptic plasticity and support long-term potentiation, the cellular mechanism underlying memory formation.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Other Recent Clinical Trials (2025-2026)<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The laromestrocel trial is part of a broader surge in MSC research for Alzheimer&#8217;s. A systematic review identified 94 stem cell clinical trials for neurodegenerative diseases, with nearly 70% of enrolled participants in AD-related studies (Isik et al., CNS Neuroscience and Therapeutics 2025).<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Korean Intraventricular MSC Trial (Lee et al., 2025)<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">At Samsung Medical Center in Seoul, 24 patients received MSCs intraventricularly three times at 4-week intervals. While clinical benefits on cognitive scales were not statistically significant, CSF biomarkers improved meaningfully. Adverse events (fever, headache, nausea) were more common in the MSC group, but co-administration of dexamethasone (15 mg) attenuated immune-related reactions and reduced CSF white blood cell counts and interleukin-6 levels. This suggests that combining MSCs with anti-inflammatory premedication may improve tolerability-a practical insight for future trial design.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Exosome-Based Approaches in Preclinical Development<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Preclinical research is advancing exosome delivery systems. MSC-derived exosomes coated with PLGA nanoparticles can clear pathological proteins by remodeling lysosomal function in AD models (Gu et al., Nanomedicine 2026). Baicalein-encapsulated human umbilical cord MSC exosomes modulate oxidative stress and neuroinflammation in rat hippocampal neurons (Xu et al., Biomaterials Advances 2026). These engineered exosome formulations represent the next generation of cell-free MSC therapy.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Active ClinicalTrials.gov Registrations<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Multiple Phase I\/II trials are currently recruiting or active on ClinicalTrials.gov, investigating:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Intravenous vs intrathecal vs intraventricular delivery routes and their relative brain exposure<\/li>\n\n\n\n<li>Autologous (patient-derived) vs allogeneic (donor) MSC sources and consistency of response<\/li>\n\n\n\n<li>Preconditioned MSCs with enhanced exosome secretion and neuroprotective cargo<\/li>\n\n\n\n<li>Combination strategies pairing MSCs with anti-inflammatory agents or anti-amyloid antibodies<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">What This Means for Patients and Families<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The 2025-2026 clinical data represent a turning point for the field. For the first time, we have rigorous evidence that MSC therapy can:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Be administered safely in elderly patients (mean age 70+)<\/li>\n\n\n\n<li>Slow brain atrophy in the hippocampus and whole brain by 48-62%<\/li>\n\n\n\n<li>Reduce neuroinflammation as measured by DTI<\/li>\n\n\n\n<li>Modify CSF biomarkers of Alzheimer&#8217;s pathology (amyloid-beta, p-tau, t-tau)<\/li>\n\n\n\n<li>Show trends toward improved cognition and daily living scores<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">These are disease-modifying effects-the kind of outcomes that current standard-of-care medications struggle to achieve. While the FDA has approved lecanemab and donanemab for amyloid clearance, both carry significant ARIA risks and provide modest clinical benefit (27-35% slowing of decline on cognitive scales). MSC therapy may offer a complementary or alternative pathway.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Timing Matters: Early Intervention is Key<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The laromestrocel trial enrolled patients with <em>mild<\/em> Alzheimer&#8217;s disease. This is important-MSC therapy works best when there is still viable brain tissue to protect. Once extensive neuronal loss has occurred, regeneration becomes much more challenging. For patients in the prodromal stage (mild cognitive impairment) or early dementia, MSC therapy may offer the best window for meaningful intervention. We recommend early screening and evaluation rather than waiting for significant decline.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Frequently Asked Questions<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">Is MSC therapy for Alzheimer&#8217;s available now?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Clinical trials are ongoing, and some compassionate-use programs exist. At Cell La Vie, we monitor these developments closely and can discuss emerging treatment options for eligible patients. Contact our clinic to learn about trial eligibility and access to therapies in Thailand.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">What type of stem cells are used in Alzheimer&#8217;s trials?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Most trials use mesenchymal stem cells from bone marrow (BM-MSCs), umbilical cord (UC-MSCs), or adipose tissue. Allogeneic (donor-derived) cells are preferred because they can be manufactured at scale, quality-controlled, and administered without the delays and procedural risks of harvesting cells from elderly patients.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">How is the treatment administered?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Three routes are under investigation: intravenous (IV) infusion is the least invasive and most accessible; intrathecal injection delivers cells to the cerebrospinal fluid; and intraventricular administration places cells directly into the brain&#8217;s ventricles. IV administration is the most practical for routine clinical use.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">\u6709\u4ec0\u4e48\u526f\u4f5c\u7528\uff1f<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">In the laromestrocel trial, treatment-emergent adverse events were minimal and similar to placebo. The Korean trial reported transient fever, headache, and nausea, which responded to dexamethasone premedication. No serious adverse events were attributed to the MSCs themselves. This is a favorable safety profile compared to anti-amyloid antibodies.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">How long do the effects last?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Current data show sustained benefits at 39 weeks after the initial infusion series. Long-term durability is being studied in ongoing Phase II\/III trials. Based on other MSC indications, some patients may benefit from periodic booster infusions.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Is MSC therapy covered by insurance?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Most insurance plans do not yet cover stem cell therapies for Alzheimer&#8217;s. However, Thailand offers a significant cost advantage for medical tourism, with treatment costs 60-80% lower than comparable protocols in the U.S. or Europe. Our clinic can discuss pricing and financing options during your consultation.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Who is a good candidate?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Patients with mild Alzheimer&#8217;s or mild cognitive impairment (MCI) are ideal candidates. Those with advanced dementia may have limited benefit due to extensive neuronal loss. A full neurological evaluation, cognitive testing, and imaging workup are needed to determine eligibility. Family members are encouraged to attend the initial consultation.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">\u53c2\u8003<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Rash BG<\/strong> et al. Allogeneic mesenchymal stem cell therapy with laromestrocel in mild Alzheimer&#8217;s disease: a randomized controlled phase 2a trial. <em>Nature Medicine<\/em>. 2025 Apr;31(4):1257-1266. DOI: 10.1038\/s41591-025-03559-0<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Lee NK<\/strong> et al. Mesenchymal Stem Cells With Adjuvant Dexamethasone in Patients With Alzheimer&#8217;s Disease: A Phase IIa Trial. <em>Dementia and Neurocognitive Disorders<\/em>. 2025 Oct;24(4):272-285. DOI: 10.12779\/dnd.2025.24.4.272<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Patil VS<\/strong> et al. Therapeutic and Diagnostic Roles of MSC-Derived Exosomes in Alzheimer&#8217;s Disease. <em>Brain and Behavior<\/em>. 2025 Dec;15(12):e71112. DOI: 10.1002\/brb3.71112<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Isakovic J<\/strong> et al. Stem cells strike back: advancements in Alzheimer&#8217;s and Parkinson&#8217;s disease treatment and modeling efforts from 2019 to 2024. <em>Journal of Molecular Medicine<\/em>. 2025 Dec;104(1):2. DOI: 10.1007\/s00109-025-02613-1<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Isik S<\/strong> et al. Advances in Neurodegenerative Disease Therapy: Stem Cell Clinical Trials and Promise of Engineered Exosomes. <em>CNS Neuroscience and Therapeutics<\/em>. 2025 Sep;31(9):e70577. DOI: 10.1111\/cns.70577<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Gu Y<\/strong> et al. Mesenchymal stem cell-derived nanovesicles coated PLGA nanoparticle (MSC-PLGA-NPs) remodel lysosomal function to clear pathological proteins in Alzheimer&#8217;s disease models. <em>Nanomedicine<\/em>. 2026 Jan. DOI: 10.1080\/17435889.2025.2588421<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Xu J<\/strong> et al. Nanotherapeutic potential of Baicalein-encapsulated hUC-MSC exosomes in Alzheimer&#8217;s disease: Modulating oxidative stress and neuroinflammation. <em>Biomaterials Advances<\/em>. 2026 Apr. DOI: 10.1016\/j.bioadv.2025.214619<\/p>\n\n\n\n\n<div class=\"wp-block-button is-style-fill is-content-justification-center is-layout-flex wp-container-core-buttons-is-layout-fe48e5de wp-block-buttons-is-layout-flex\"><a class=\"wp-block-button__link has-white-color has-green-background-color has-text-color has-background\" href=\"https:\/\/cell-lavie.com\/zh\/#contact\" style=\"font-size:18px;padding:14px 32px\">Book Your Free Consultation \u2192<\/a><\/div>\n\n\n<div class=\"wp-block-button is-style-fill\"><a class=\"wp-block-button__link has-black-color has-luminous-vivid-amber-background-color has-text-color has-background\" href=\"https:\/\/cell-lavie.com\/zh\/free-candidacy-assessment\/\" style=\"font-size:18px;padding:14px 32px\">Free Candidacy Assessment \u2192<\/a><\/div>","protected":false},"excerpt":{"rendered":"<p>Recent Phase 2a clinical trials demonstrate that mesenchymal stem cell therapy can slow brain atrophy by up to 62% and reduce neuroinflammation in mild Alzheimer&#8217;s patients. Review of laromestrocel trial data, biomarker outcomes, and emerging treatment options.<\/p>","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_seopress_titles_title":"MSC Therapy for Alzheimer's Disease: 2026 Clinical Trial Data | Cell La Vie","_seopress_titles_desc":"New Phase 2a trial shows MSC therapy slows brain atrophy by 62% in Alzheimer's. Review of laromestrocel data, safety outcomes, and treatment options in Thailand.","_seopress_robots_index":"","_seopress_robots_follow":"","_seopress_robots_imageindex":"","_seopress_robots_snippet":"","_seopress_robots_primary_cat":"","_seopress_robots_breadcrumbs":"","_seopress_robots_freeze_modified_date":"","_seopress_robots_custom_modified_date":"","_seopress_robots_canonical":"","_seopress_social_fb_title":"","_seopress_social_fb_desc":"","_seopress_social_fb_img":"","_seopress_social_fb_img_attachment_id":0,"_seopress_social_fb_img_width":0,"_seopress_social_fb_img_height":0,"_seopress_social_twitter_title":"","_seopress_social_twitter_desc":"","_seopress_social_twitter_img":"","_seopress_social_twitter_img_attachment_id":0,"_seopress_social_twitter_img_width":0,"_seopress_social_twitter_img_height":0,"_seopress_redirections_value":"","_seopress_redirections_enabled":"","_seopress_redirections_enabled_regex":"","_seopress_redirections_logged_status":"","_seopress_redirections_param":"","_seopress_redirections_type":0,"_seopress_analysis_target_kw":"","_sitemap_exclude":false,"_sitemap_priority":"","_sitemap_frequency":"","footnotes":""},"categories":[102,83,71],"tags":[145,189,190,84,198,92,81],"class_list":["post-201095","post","type-post","status-publish","format-standard","hentry","category-alzheimer","category-mscs","category-stem-cells","tag-allogeneic-msc","tag-msc-immunomodulation","tag-msc-therapy","tag-mscs","tag-regenerative-medicine","tag-stem-cell","tag-stem-cells"],"featured_image_src":{"landsacpe":false,"list":false,"medium":false,"full":false},"_links":{"self":[{"href":"https:\/\/cell-lavie.com\/zh\/wp-json\/wp\/v2\/posts\/201095","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cell-lavie.com\/zh\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cell-lavie.com\/zh\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cell-lavie.com\/zh\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/cell-lavie.com\/zh\/wp-json\/wp\/v2\/comments?post=201095"}],"version-history":[{"count":1,"href":"https:\/\/cell-lavie.com\/zh\/wp-json\/wp\/v2\/posts\/201095\/revisions"}],"predecessor-version":[{"id":201128,"href":"https:\/\/cell-lavie.com\/zh\/wp-json\/wp\/v2\/posts\/201095\/revisions\/201128"}],"wp:attachment":[{"href":"https:\/\/cell-lavie.com\/zh\/wp-json\/wp\/v2\/media?parent=201095"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cell-lavie.com\/zh\/wp-json\/wp\/v2\/categories?post=201095"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cell-lavie.com\/zh\/wp-json\/wp\/v2\/tags?post=201095"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}